Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Dr.-Muhit-Ozcan"

1 News Found

Merck’s investigational ADC with R-CHP demonstrates 100% response rate for B-cell lymphoma
Diagnostic Center | December 09, 2024

Merck’s investigational ADC with R-CHP demonstrates 100% response rate for B-cell lymphoma

Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate